ABVC BioPharma (ABVC) Competitors $0.52 +0.01 (+1.22%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ABVC vs. NAII, PLUR, ENLV, SNTI, AKTX, EQ, CLDI, CMMB, LSB, and INKTShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include Natural Alternatives International (NAII), Pluri (PLUR), Enlivex Therapeutics (ENLV), Senti Biosciences (SNTI), Akari Therapeutics (AKTX), Equillium (EQ), Calidi Biotherapeutics (CLDI), Chemomab Therapeutics (CMMB), Lakeshore Biopharma (LSB), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. Natural Alternatives International Pluri Enlivex Therapeutics Senti Biosciences Akari Therapeutics Equillium Calidi Biotherapeutics Chemomab Therapeutics Lakeshore Biopharma MiNK Therapeutics Natural Alternatives International (NASDAQ:NAII) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership. Does the media prefer NAII or ABVC? In the previous week, ABVC BioPharma had 2 more articles in the media than Natural Alternatives International. MarketBeat recorded 2 mentions for ABVC BioPharma and 0 mentions for Natural Alternatives International. ABVC BioPharma's average media sentiment score of 0.44 beat Natural Alternatives International's score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Natural Alternatives International Neutral ABVC BioPharma Neutral Is NAII or ABVC more profitable? Natural Alternatives International has a net margin of -7.53% compared to ABVC BioPharma's net margin of -1,619.65%. Natural Alternatives International's return on equity of -10.23% beat ABVC BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Natural Alternatives International-7.53% -10.23% -5.38% ABVC BioPharma -1,619.65%-104.94%-56.81% Do insiders & institutionals have more ownership in NAII or ABVC? 32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 20.9% of Natural Alternatives International shares are held by insiders. Comparatively, 11.9% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in NAII or ABVC? Natural Alternatives International received 258 more outperform votes than ABVC BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformNatural Alternatives InternationalOutperform Votes25875.66% Underperform Votes8324.34% ABVC BioPharmaN/AN/A Which has stronger valuation & earnings, NAII or ABVC? Natural Alternatives International has higher revenue and earnings than ABVC BioPharma. Natural Alternatives International is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNatural Alternatives International$112.98M0.23-$7.22M-$1.44-2.94ABVC BioPharma$509.79K13.34-$10.52M-$0.86-0.61 Which has more volatility & risk, NAII or ABVC? Natural Alternatives International has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. SummaryNatural Alternatives International beats ABVC BioPharma on 8 of the 14 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.72M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.6110.5990.0517.18Price / Sales13.34195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / Book0.515.094.784.78Net Income-$10.52M$151.83M$120.31M$225.60M7 Day Performance3.76%-2.13%-1.92%-1.23%1 Month Performance-4.71%-3.10%11.51%3.36%1 Year Performance-52.36%11.54%30.61%16.60% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma1.0149 of 5 stars$0.52+1.2%N/A-52.8%$6.72M$509,788.00-0.6130News CoverageNAIINatural Alternatives InternationalN/A$4.23-1.6%N/A-37.1%$26.22M$112.98M-2.99290Analyst ForecastPLURPluri0.4243 of 5 stars$4.65-1.5%N/A+10.5%$25.85M$330,000.000.00150News CoverageENLVEnlivex Therapeutics2.321 of 5 stars$1.16-3.4%$9.50+719.4%-36.6%$24.82MN/A0.0070SNTISenti Biosciences2.3392 of 5 stars$5.32-4.5%$10.00+88.0%-5.2%$24.41M$2.56M-0.334News CoverageGap UpAKTXAkari TherapeuticsN/A$0.98+0.7%N/A-67.2%$24.27MN/A0.009Analyst ForecastGap DownHigh Trading VolumeEQEquillium2.9048 of 5 stars$0.66-6.0%$5.00+654.8%-16.5%$23.47M$45.91M-5.0440Gap DownCLDICalidi Biotherapeutics2.341 of 5 stars$1.79-3.5%$16.67+833.7%N/A$23.34M$50,000.000.0041News CoverageGap DownCMMBChemomab Therapeutics3.3163 of 5 stars$1.62+2.8%$7.33+351.6%+230.1%$23.32MN/A-1.5820Positive NewsLSBLakeshore Biopharma0.4967 of 5 stars$2.50+0.4%N/AN/A$23.28M$80.82M0.00773News CoverageGap UpINKTMiNK Therapeutics2.2354 of 5 stars$0.59-4.5%$6.50+1,005.1%-47.6%$23.26MN/A-1.4930Gap Up Related Companies and Tools Related Companies Natural Alternatives International Competitors Pluri Competitors Enlivex Therapeutics Competitors Senti Biosciences Competitors Akari Therapeutics Competitors Equillium Competitors Calidi Biotherapeutics Competitors Chemomab Therapeutics Competitors Lakeshore Biopharma Competitors MiNK Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABVC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
